These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34376784)

  • 1. Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases.
    Rada M; Kapelanski-Lamoureux A; Petrillo S; Tabariès S; Siegel P; Reynolds AR; Lazaris A; Metrakos P
    Commun Biol; 2021 Aug; 4(1):950. PubMed ID: 34376784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases.
    Haas G; Fan S; Ghadimi M; De Oliveira T; Conradi LC
    Front Cell Dev Biol; 2021; 9():612774. PubMed ID: 33912554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model.
    Rada M; Lazaris A; Kapelanski-Lamoureux A; Mayer TZ; Metrakos P
    Semin Cancer Biol; 2021 Jun; 71():52-64. PubMed ID: 32920126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophils expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases resistant to anti-angiogenic therapy.
    Palmieri V; Lazaris A; Mayer TZ; Petrillo SK; Alamri H; Rada M; Jarrouj G; Park WY; Gao ZH; McDonald PP; Metrakos P
    J Pathol; 2020 Jun; 251(2):213-223. PubMed ID: 32297656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular mechanisms underlying neutrophil infiltration in vessel co-opting colorectal cancer liver metastases.
    Rada M; Hassan N; Lazaris A; Metrakos P
    Front Oncol; 2022; 12():1004793. PubMed ID: 36330498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Cells Promote Phenotypic Alterations in Hepatocytes at the Edge of Cancer Cell Nests to Facilitate Vessel Co-Option Establishment in Colorectal Cancer Liver Metastases.
    Rada M; Tsamchoe M; Kapelanski-Lamoureux A; Hassan N; Bloom J; Petrillo S; Kim DH; Lazaris A; Metrakos P
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies.
    Lazaris A; Amri A; Petrillo SK; Zoroquiain P; Ibrahim N; Salman A; Gao ZH; Vermeulen PB; Metrakos P
    J Pathol Clin Res; 2018 Jul; 4(3):184-192. PubMed ID: 29654716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiopoietin-1 Upregulates Cancer Cell Motility in Colorectal Cancer Liver Metastases through Actin-Related Protein 2/3.
    Rada M; Kapelanski-Lamoureux A; Tsamchoe M; Petrillo S; Lazaris A; Metrakos P
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
    Frentzas S; Simoneau E; Bridgeman VL; Vermeulen PB; Foo S; Kostaras E; Nathan M; Wotherspoon A; Gao ZH; Shi Y; Van den Eynden G; Daley F; Peckitt C; Tan X; Salman A; Lazaris A; Gazinska P; Berg TJ; Eltahir Z; Ritsma L; Van Rheenen J; Khashper A; Brown G; Nystrom H; Sund M; Van Laere S; Loyer E; Dirix L; Cunningham D; Metrakos P; Reynolds AR
    Nat Med; 2016 Nov; 22(11):1294-1302. PubMed ID: 27748747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RUNX1 promotes tumour metastasis by activating the Wnt/β-catenin signalling pathway and EMT in colorectal cancer.
    Li Q; Lai Q; He C; Fang Y; Yan Q; Zhang Y; Wang X; Gu C; Wang Y; Ye L; Han L; Lin X; Chen J; Cai J; Li A; Liu S
    J Exp Clin Cancer Res; 2019 Aug; 38(1):334. PubMed ID: 31370857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiopoietin1 Deficiency in Hepatocytes Affects the Growth of Colorectal Cancer Liver Metastases (CRCLM).
    Ibrahim NS; Lazaris A; Rada M; Petrillo SK; Huck L; Hussain S; Ouladan S; Gao ZH; Gregorieff A; Essalmani R; Seidah NG; Metrakos P
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31877668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution.
    Fleischer JR; Schmitt AM; Haas G; Xu X; Zeisberg EM; Bohnenberger H; Küffer S; Teuwen LA; Karras PJ; Beißbarth T; Bleckmann A; Planque M; Fendt SM; Vermeulen P; Ghadimi M; Kalucka J; De Oliveira T; Conradi LC
    Mol Cancer; 2023 Jan; 22(1):17. PubMed ID: 36691028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
    Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
    J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Embryonic Stem Cell-Specific Transcription Factor ZFP57 Promotes Liver Metastasis of Colorectal Cancer.
    Shoji Y; Takamura H; Ninomiya I; Fushida S; Tada Y; Yokota T; Ohta T; Koide H
    J Surg Res; 2019 May; 237():22-29. PubMed ID: 30694787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases.
    Rada M; Krzywon L; Petrillo S; Lazaris A; Metrakos P
    Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models.
    Qi M; Fan S; Huang M; Pan J; Li Y; Miao Q; Lyu W; Li X; Deng L; Qiu S; Liu T; Deng W; Chu X; Jiang C; He W; Xia L; Yang Y; Hong J; Qi Q; Yin W; Liu X; Shi C; Chen M; Ye W; Zhang D
    J Clin Invest; 2022 Oct; 132(19):. PubMed ID: 35951441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RUNX1 regulates TGF-β induced migration and EMT in colorectal cancer.
    Lu C; Yang Z; Yu D; Lin J; Cai W
    Pathol Res Pract; 2020 Nov; 216(11):153142. PubMed ID: 32866710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value.
    Barnhill R; van Dam PJ; Vermeulen P; Champenois G; Nicolas A; Rawson RV; Wilmott JS; Thompson JF; Long GV; Cassoux N; Roman-Roman S; Busam KJ; Scolyer RA; Lazar AJ; Lugassy C
    J Pathol Clin Res; 2020 Jul; 6(3):195-206. PubMed ID: 32304183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-215 promotes malignant progression of gastric cancer by targeting RUNX1.
    Li N; Zhang QY; Zou JL; Li ZW; Tian TT; Dong B; Liu XJ; Ge S; Zhu Y; Gao J; Shen L
    Oncotarget; 2016 Jan; 7(4):4817-28. PubMed ID: 26716895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue inhibitor of matrix metalloproteinase-1 expression in colorectal cancer liver metastases is associated with vascular structures.
    Illemann M; Eefsen RH; Bird NC; Majeed A; Osterlind K; Laerum OD; Alpízar-Alpízar W; Lund IK; Høyer-Hansen G
    Mol Carcinog; 2016 Feb; 55(2):193-208. PubMed ID: 25594187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.